Highlights RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Market Closed - Hong Kong S.E. Other stock markets 04:08:24 2024-07-08 am EDT			5-day change	1st Jan Change
17.56 ^HKD	-18.70%		-28.33%	-53.11%

Jun. 14	RemeGen Phase Three Breast Cancer Clinical Trial Meets Primary Endpoint; Shares Rise 3%	MT
Jun. 13	RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RemeGen Phase Three Breast Cancer Clinical Trial Meets Primary Endpoint; Shares Rise 3%	Jun. 13	MT
RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint	Jun. 13	CI
RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS	Apr. 02	CI
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024	Mar. 10	CI
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40%	Feb. 26	MT
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
RemeGen's Loss to Widen in 2023	Jan. 31	MT
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	Jan. 30	CI
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares	Jan. 23	MT
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles	Jan. 17	MT
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients	Jan. 12	CI
RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment	Dec. 28	CI
RemeGen Gets Full Approval for Telitacicept	Nov. 22	MT
RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA	Nov. 22	CI
RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology	Nov. 15	CI
RemeGen Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
ImmuneOnco Biopharmaceuticals Raises HK$234.5 Million in Hong Kong IPO	23-09-03	MT
ImmuneOnco Biopharmaceuticals Launches Up to HK$319 Million Hong Kong IPO	23-08-23	MT
RemeGen Completes Phase III Study of Arthritis Drug in China	23-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Highlights

Filters